Relay Therapeutics Inc (NASDAQ: RLAY)’s stock price has soared by 2.14 in relation to previous closing price of 2.57. Nevertheless, the company has seen a gain of 31.25% in its stock price over the last five trading days. seekingalpha.com reported 2025-04-12 that Relay Therapeutics’ pipeline has shifted, with the FGFR2 inhibitor lirafugratinib outlicensed to Elevar, bringing in cash and royalties, but losing global rights. RLY-2608, a PI3K-alpha inhibitor, shows promise in breast cancer trials, with plans for a phase 3 trial and potential in other cancers. Financially, RLAY holds $124.3M in cash and $657M in investments, with a cash runway into mid-2026, bolstered by recent cost-saving measures.
Is It Worth Investing in Relay Therapeutics Inc (NASDAQ: RLAY) Right Now?
RLAY has 36-month beta value of 1.67. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RLAY is 127.71M, and currently, short sellers hold a 14.14% ratio of that float. The average trading volume of RLAY on April 15, 2025 was 2.42M shares.
RLAY’s Market Performance
RLAY stock saw a decrease of 31.25% in the past week, with a monthly decline of -25.21% and a quarterly a decrease of -39.59%. The volatility ratio for the week is 15.41%, and the volatility levels for the last 30 days are 9.71% for Relay Therapeutics Inc (RLAY). The simple moving average for the past 20 days is 0.32% for RLAY’s stock, with a -51.99% simple moving average for the past 200 days.
Analysts’ Opinion of RLAY
Many brokerage firms have already submitted their reports for RLAY stocks, with Jefferies repeating the rating for RLAY by listing it as a “Buy.” The predicted price for RLAY in the upcoming period, according to Jefferies is $16 based on the research report published on September 10, 2024 of the previous year 2024.
Goldman, on the other hand, stated in their research note that they expect to see RLAY reach a price target of $20. The rating they have provided for RLAY stocks is “Buy” according to the report published on September 10th, 2024.
RLAY Trading at -20.46% from the 50-Day Moving Average
After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.51% of loss for the given period.
Volatility was left at 9.71%, however, over the last 30 days, the volatility rate increased by 15.41%, as shares sank -20.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.28% lower at present.
During the last 5 trading sessions, RLAY rose by +31.25%, which changed the moving average for the period of 200-days by -58.33% in comparison to the 20-day moving average, which settled at $2.62. In addition, Relay Therapeutics Inc saw -36.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLAY starting from Bergstrom Donald A, who sale 986 shares at the price of $2.84 back on Mar 27 ’25. After this action, Bergstrom Donald A now owns 615,052 shares of Relay Therapeutics Inc, valued at $2,800 using the latest closing price.
Rahmer Peter, the of Relay Therapeutics Inc, sale 247 shares at $2.84 during a trade that took place back on Mar 27 ’25, which means that Rahmer Peter is holding 402,184 shares at $701 based on the most recent closing price.
Stock Fundamentals for RLAY
Current profitability levels for the company are sitting at:
- -38.54 for the present operating margin
- 0.72 for the gross margin
The net margin for Relay Therapeutics Inc stands at -33.75. The total capital return value is set at -0.47. Equity return is now at value -44.15, with -39.38 for asset returns.
Based on Relay Therapeutics Inc (RLAY), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -5.14.
Currently, EBITDA for the company is -380.21 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of 35.96. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.95.
Conclusion
To put it simply, Relay Therapeutics Inc (RLAY) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
